Prognia
Drug Database
🇪🇺EU · EMAAuthorisedATC: L04AD02

Envarsus(tacrolimus)

Graft Rejection

Marketing Authorisation Holder: Chiesi Farmaceutici S.p.A.

EMA Authorisation: 18/07/2014

INN: tacrolimus

Indication

Prophylaxis of transplant rejection in adult kidney or liver allograft recipients. Treatment of allograft rejection resistant to treatment with other immunosuppressive medicinal products in adult patients.

Official EMA Resources

View on EMA (ema.europa.eu)

AI Drug & Interaction Analysis

Free account required

Ask Prognia AI about Envarsus — dosing recommendations, drug interactions, and current guideline evidence from ESC, EMA, NICE and more.

Medical disclaimer: This information is intended for qualified healthcare professionals. Always verify with the official EMA Summary of Product Characteristics (SmPC) before clinical use.